LIPOPROTEIN (A), COAGULATION AND FIBRINOLYSIS

脂蛋白(A)(Lp(A))是一种低密度脂蛋白。高 脂蛋白(A)水平与动脉粥样硬化性疾病高度相关 但其机制尚不清楚。这就是我们的假设 这在一定程度上可以归因于 Lp(A)水平升高引起的纤溶系统。 本实验室的初步研究表明，Lp(A)是一种 Lp(A)结合的竞争性纤溶酶原激活抑制物 对于一种类型的纤溶酶原激活剂，Lp(A)阻断结合 纤溶酶原对其受体的作用以及在正常人和 Lp(A)水平升高的患者的亚单位分子量 Apo(A)具有不同的分布模式。现建议： 系统研究：1)Lp(A)对纤溶酶原的影响 链激酶-纤溶酶复合体、尿激活剂催化的活化作用 和组织纤溶酶原激活物；2)脂蛋白(A)水平对 纤溶酶原与内皮细胞和单核细胞样蛋白的结合(U-937) Lp(A)对纤溶酶原相互作用的影响 用纤维蛋白。作为这些研究的一部分，直接结合 与这些细胞的载脂蛋白(A)也将进行研究。Lp(A)的影响 组织型纤溶酶原激活剂与内皮细胞结合的研究 纤维蛋白也将被检查。

Lipoprotein (a) (Lp(a) is a form of low density lipoprotein. High levels of Lp(a) are highly correlated with atherosclerotic diseAse but the mechanism is unknown. It is the hypothesis of this application that, in part, this may be attributed to disorders in the fibrinolytic system induced by increased levels of Lp(a). Preliminary studies in this laboratory indicate that Lp(a) is a competitive inhibitor of plasminogen activation, that Lp(a) binds to one type of plasminogen activator, that Lp(a) blocks the binding of plasminogen to its receptor and that in normal subjects and patients with high Lp(a) levels the subunit molecular weight for apo(a) has a different distribution pattern. It is proposed to systematically study: 1) the effect of Lp(a) on plasminogen activation catalyzed by streptokinase-plasmin complexes, urokinase and tissue plasminogen activator; 2) the effect of Lp(a) levels on the binding of plasminogen to endothelial and monocyte-like (U-937) cells; 3) the effect of Lp(a) on the interaction of plasminogen with fibrin. As part of these studies, the direct binding of apo(a) with these cells will also be studied. The effect of Lp(a) on the binding of tissue plasminogen activator to endothelial cells and fibrin will also be examined.